The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Improving the efficacy of immunotherapy using anti-angiogenic agents in GI malignancies
Hans Prenen, MD, PhD, UZ Leuven, Leuven, Belgium, discusses key data presented at this years American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, including the combined use of anti-angiogenic factors with immunotherapy as evaluated in the LEAP-005 study (NCT03797326) which combined a checkpoint inhibitor with lenvatinib. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
